Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Roche halts diabetes trial in light of safety concerns
August 2013
SHARING OPTIONS:

BASEL—Roche has terminated its aleglitazar AleCardio Phase III trial and all other trials involving aleglitazar following a regular safety review and the recommendation by the independent Data and Safety Monitoring Board that the trial be halted due to safety signals and lack of efficacy. The trial was evaluating aleglitazar's safety and efficacy in patients with type 2 diabetes that had recently had an acute coronary syndrome event.  
 
"The safety of patients is our first priority. Roche is working with investigators to support the management of patients and their transition from aleglitazar treatment to other blood sugar control therapies," said Dr. Hal Barron, chief medical officer and head of global product development at Roche. "We are disappointed by this outcome as we hoped that aleglitazar would provide significant benefit for patients with type 2 diabetes who are at risk of cardiovascular disease."
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.